


Case 21230YP

Page 2


In the Claims

1. (Currently Amended) A compound represented by Formula (I) or (II):




(I)

or



(II)


or a pharmaceutically acceptable salt thereof, wherein
HET-1 is one of the following heterocycles:



HET-2 is one of the following heterocycles:

Case 21230YP

Page 3

R¹ is:

- (a) H;
- (b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₆-cycloalkyl, or C₁-C₄-alkyl-[C₁-C₆-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (c) -O-C₁-C₆-alkyl, -O-C₁-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, O-CONR^aR^b, NR^aR^b, N(R^a)CONR^aR^b, COO-(C₁-C₄)alkyl, COOH, CN, CONR^aR^b, SO₂NR^aR^b, N(R^a)SO₂NR^aR^b, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
- (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;
- (e) -OH;
- (f) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-

Case 21230YP

Page 4

O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

(g) -OCON(R^a)(R^b), or -OSO₂N(R^a)(R^b);

(h) -SH, or -SCON(R^a)(R^b);

(i) NO₂;

(j) NR^aR^b, -N(COR^a)R^b, -N(SO₂R^a)R^b, -N(R^a)CON(R^a)₂, -N(R^a)CONH₂, -N(OR^a)CONR^aR^b, -N(R^a)CON(R^a)₂, or -N(R^a)SO₂N(R^a)₂;


(k) -CH(OR^a)R^a, -C(OR^b)CF₃, -CH(NHR^b)R^a, -C(=O)R^a, C(=O)CF₃, -SOCH₃, -SO₂CH₃, -N(R^a)SO₂R^a, COOR^a, CN, CONR^aR^b, -COCONR^aR^b, -SO₂NR^aR^b, -CH₂O-SO₂NR^aR^b, SO₂N(R^a)OR^a, -C(=NH)NH₂, -CRA=N-OR^a, CH=CHCONR^aR^b, CONR^a, CONHR^a;

(l) -CONR^a(CH₂)₀₋₂C(R^a)(R^b)(CH₂)₀₋₂CONR^aR^b;

(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 independent substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)R^a, v) C₁-C₆-alkyl, vi) -O-R^a, vii) -NR^aR^b, viii) -C₀-C₄-alkyl -CO-O R^a, ix) -(C₀-C₄-alkyl)-NH-CO-OR^a, x) -(C₀-C₄-alkyl)-CO-NR^aR^b, xi) -S(O)₀₋₂R^a, xii) -SO₂NR^aR^b, xiii) -NHSO₂R^a, xiv) -C₁-C₄-perfluoroalkyl, and xv) -O-C₁-C₄-perfluoroalkyl;

(n) -C(R^a)=C(R^b)-COOR^a, or -C(R^a)=C(R^b)-CONR^aR^b;

(o) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from



i) -CN, ii) -C(=O)(R^a), iii) C₁-C₆-alkyl, iv) -OR^a, v) -NR^aR^b, vi) -C₀-C₄-alkyl-CO-OR^a, vii) -(C₀-C₄-alkyl)-NH-CO-OR^a, viii) -(C₀-C₄-alkyl)-CON(R^a)(R^b), ix) -SR^a, x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a xiii) -C₁-C₄-perfluoroalkyl and xiv) -O-C₁-C₄-perfluoroalkyl;

R^a is

(a) H;

(b) C₁-C₄-alkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, -OCONH₂, -OCONH(C₁-C₄alkyl), -OCON(C₁-C₄alkyl)(C₁-C₄alkyl), -OCONH(C₁-C₄alkyl-aryl), -OCON(C₁-C₄alkyl)(C₁-C₄alkyl-aryl), NH₂, NH(C₁-C₄alkyl), N(C₁-C₄alkyl)(C₁-C₄alkyl), NH(C₁-C₄alkyl)-

Case 21230YP

Page 5

aryl), N(C₁-C₄alkyl)(C₁-C₄alkyl-aryl), NHCONH₂, NHCONH(C₁-C₄alkyl), NHCONH(C₁-C₄alkyl-aryl), -NHCON(C₁-C₄alkyl)(C₁-C₄alkyl), NHCON(C₁-C₄alkyl)(C₁-C₄alkyl-aryl), N(C₁-C₄alkyl)CON(C₁-C₄alkyl)(C₁-C₄alkyl), N(C₁-C₄alkyl)CON(C₁-C₄alkyl)(C₁-C₄alkyl-aryl), COO-(C₁-C₄-alkyl), COOH, CN, CONH₂, CONH(C₁-C₄alkyl), CON(C₁-C₄alkyl)(C₁-C₄alkyl), SO₂NH₂, SO₂NH(C₁-C₄alkyl), SO₂NH(C₁-C₄alkyl-aryl), SO₂N(C₁-C₄alkyl)(C₁-C₄alkyl), NHSO₂NH₂, -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) C₀-C₄-alkyl-(C₁-C₄)-perfluoroalkyl; or

(d) C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(C₁-C₄-alkyl), v) -O(C₁-C₄-alkyl), vi) -N(C₁-C₄-alkyl)(C₁-C₄-alkyl), vii) -C₁-10alkyl, and viii) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;

R^b is

(a) H; or

(b) C₁-C₆-alkyl, optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)alkyl, S(O)₀₋₂-(C₁-C₄)alkyl, -OCONH₂, -OCONH(C₁-C₄alkyl), NH₂, NH, NH(C₁-C₄alkyl), N(C₁-C₄alkyl), N(C₁-C₄alkyl)(C₁-C₄alkyl), NHCONH₂, NHCONH(C₁-C₄alkyl), -NHCON(C₁-C₄alkyl)(C₁-C₄alkyl), COO-(C₁-C₄-alkyl), COOH, CN, pyridyl, piperidinyl, pyrimidinyl, piperazinyl, CONH₂ or (C₁-C₄alkyl)CONH₂; or

R^a and R^b, together with the N to which they are attached, can form a 5- or 6-membered ring which optionally contains a heteroatom selected from N, O, and S, and wherein said ring is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -O-;

R² and R³ each independently is:

(a) H;

Case 21230YP

Page 6

- (b) -C₁-C₄-alkyl, or -O-C₁-C₄-alkyl;
 (c) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
 (d) CN, N R^a R^b, NO₂, F, Cl, Br, I, OH, OCONR^a R^b, O(C₁-C₄-alkyl)CONR^a R^b, -OSO₂NR^a R^b, COOR^a, or CONR^a R^b;

R⁴ and R⁵ each independently is:

- (a) H;
 (b) -C₁-C₆-alkyl, -C₂-C₆-alkenyl, -C₂-C₆-alkynyl or -C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, -O-(C₁-C₄)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C₁-C₄)alkyl, COOR^b, CON(R^a)(R^b) and phenyl;
 (c) -O-C₀-C₆-alkyl, -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀-4alkyl-CO-OR^a, viii) -(C₀-4alkyl)-NH-CO-OR^a, ix) -(C₀-4alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
 (d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl; or
 (e) CN, NH₂, NO₂, F, Cl, Br, I, OH, OCON(R^a)(R^b) O(C₁-C₄-alkyl)CONR^aR^b, -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀-4alkyl-CO-OR^a, viii) -(C₀-4alkyl)-NH-CO-OR^a, ix) -(C₀-4alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁-10alkyl, and xiv) -C₁-10alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; and

R⁶, R⁷ and R⁸ each independently is:

- (a) H;
 (b) C₁-C₆-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl or C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-

Case 21230YP

Page 7

C₄alkyl, OCON(R^a)(R^b), NR^aR^b, COOR^a, CN, CONR^aR^b, N(R^a)CONR^aR^b, N(R^a)SO₂NR^aR^b, SO₂NR^aR^b, S(O)₀₋₂(C₁-C₄-alkyl), -C(=NH)NH₂, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, and piperazinyl;

(c) -O-C₁-C₆-alkyl, -O-C₁-C₆-cycloalkyl, -S-C₁-C₆-alkyl or -S-C₁-C₆-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF₃, OH, O-(C₁-C₄)-alkyl, NH₂, NH(C₁-C₄-alkyl), N(C₁-C₄-alkyl)₂, COOH, CN, CONH₂, CONH(C₁-C₄-alkyl), CONH(C₁-C₄-alkyl)₂, SO₂NH₂, SO₂NH(C₁-C₄-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) -C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl, or -O-C₀-C₄-alkyl-C₁-C₄-perfluoroalkyl;

(e) -O-aryl, or -O-C₁-C₄-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; or

(f) CN, N(R^a)(R^b), NO₂, F, Cl, Br, I, -OR^a, -SR^a, -OCON(R^a)(R^b), -OSO₂N(R^a)(R^b), COOR^b, CON(R^a)(R^b), -N(R^a)CON(R^a)(R^b), -N(R^a)SO₂N(R^a)(R^b), -C(OR^b)R^a, -C(OR^a)CF₃, -C(NHR^a)CF₃, -C(=O)R^a, C(=O)CF₃, -SOCH₃, -SO₂CH₃, -NH₂SO₂(C₁₋₆-alkyl), -NH₂SO₂-aryl, SO₂N(R^a)(R^b), -CH₂OSO₂N(R^a)(R^b), SO₂N(R^b)-OR^a, -C(=NH)NH₂, -CR^a=N-OR^a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO₂, iv) -C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C₀₋₄alkyl-CO-OR^a, viii) -(C₀₋₄alkyl)-NH-CO-OR^a, ix) -(C₀₋₄alkyl)-CO-N(R^a)(R^b), x) -S(O)₀₋₂R^a, xi) -SO₂N(R^a)(R^b), xii) -NR^aSO₂R^a, xiii) -C₁₋₁₀alkyl, and xiv) -C₁₋₁₀alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; or when R⁶ and R⁷ are present on adjacent carbon


Case 21230YP

Page 8

atoms, R⁶ and R⁷, together with the benzene ring to which they are attached, can form a bicyclic aromatic ring selected from naphthyl, indolyl, quinoliny, isoquinoliny, quinoxaliny, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) -NO₂, iv) -CHO, v) -O-C₁₋₄alkyl, vi) -N(C₀₋₄alkyl)(C₀₋₄alkyl), vii) -C₀₋₄alkyl-CO-O(C₀₋₄alkyl), viii) -(C₀₋₄alkyl)-NH-CO-O(C₀₋₄alkyl), ix) -(C₀₋₄alkyl)-CO-N(C₀₋₄alkyl)(C₀₋₄alkyl), x) -S(C₀₋₄alkyl), xi) -S(O)(C₁₋₄alkyl), xii) -SO₂(C₀₋₄alkyl), xiii) -SO₂N(C₀₋₄alkyl)(C₀₋₄alkyl), xiv) -NHSO₂(C₀₋₄alkyl)(C₀₋₄alkyl), xv) -C₁₋₁₀alkyl and xvi) -C₁₋₁₀alkyl in which one or more of the carbons can be replaced by a -N(C₀₋₆alkyl)-, -O-, -S(O)₁₋₂-, -O-C(O)-, -C(O)-O-, -C(O)-N(C₀₋₆alkyl)-, -N(C₀₋₆alkyl)-C(O)-, -N(C₀₋₆alkyl)-C(O)-N(C₀₋₆alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-;

with the proviso that compounds of formula I exclude compounds wherein one of R⁴ and R⁵ is hydrogen and the other is 2-OH and two of R⁶, R⁷, and R⁸ are hydrogen and the other is -OH in the para position;

with the proviso that compounds of formula II exclude compounds wherein HET-1 is



and excluding 4-(4-aminophenyl)-6-(4'-methoxybiphenyl-3-yl)pyrimidin-2-amine.

2. (Original) The compound according to Claim 1 represented by Formula (I), or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Canceled)

5. (Canceled)


6. (Canceled)

Case 21230YP

Page 9


7. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




8. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



9. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



10. (Canceled)

11. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

R⁶ is other than H and is attached at the ortho position.


12. (Original) The compound according to Claim 1 represented by Formula (II), or a pharmaceutically acceptable salt thereof.

13. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

Case 21230YP


Page 10

HET-2 is




14. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is




15. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



16. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-2 is



Case 21230YP


Page 11

17. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein HET-2 is




18. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



19. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein


HET-2 is



20. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein HET-2 is

Case 21230YP


Page 12




21. (Cancelled)

22. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




HET-2 is



23. (Canceled)

24. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




25. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

Case 21230YP


Page 13

HET-1 is




26. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




27. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



28. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




Case 21230YP

Page 14


29. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is




30. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



31. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is









32. (Canceled)

33. (Original) A compound represented by


Case 21230YP



Page 15

or a pharmaceutically acceptable salt thereof.




34. (Original) The compound of Claim 1 represented by



R ⁶	R ⁷	R ²	R ¹
OCF ₃	H	H	H
OCF ₃	H	H	
OCF ₃	H	H	-SCH ₃
OCF ₃	H	H	-SO ₂ CH ₃
OCF ₃	H	H	-SOCH ₃
OCF ₃	H	H	NH ₂
OCF ₃	H	H	NHSO ₂ CH ₃
OCF ₃	H	H	N(SO ₂ CH ₃) ₂
OCF ₃	H	H	NHCO(CH ₃) ₃
OCF ₃	H	H	CON(CH ₃)OCH ₃
OCF ₃	H	H	
OCF ₃	H	H	CH ₃ CO
OCF ₃	H	H	CONHC(CH ₃) ₂ COOCH ₃
OCF ₃	H	H	CONHCH ₂ CH ₂ CN
OCF ₃	H	H	CONHC(CH ₃) ₂ COOH



Case 21230YP

Page 16

R ⁶	R ⁷	R ²	R ¹
OCF ₃	H	H	CONHC(CH ₃) ₂ CONH ₂
OCF ₃	H	H	CON(CH ₂ CH ₂) ₂ NH
OCF ₃	H	H	
OCF ₃	H	H	CONHC(CH ₂) ₂ COOCH ₃
OCF ₃	H	H	CONHC(CH ₂) ₂ COOH
OCF ₃	H	H	CONHC(CH ₂) ₂ CONH ₂
OCF ₃	H	H	CON(CH ₂) ₂ N(CH ₃) ₂
OCF ₃	H	H	CONHCH ₃
OCF ₃	H	H	CON(CH ₃) ₂
OCF ₃	H	H	COOCH ₃
OCF ₃	H	H	CONHCH(CH ₃)CONH ₂ (S)
OCF ₃	H	H	CON(CH ₂) ₂ 
OCF ₃	H	H	CONHC(CH ₃) ₃
OCF ₃	H	H	CON(CH ₃) ₂ CH ₂ OH
OCF ₃	H	H	CONHCH(CH ₃)CONH ₂ (R)
OCF ₃	H	H	
OCF ₃	H	CH ₃	CH ₃
OCF ₃	H	CH ₃	COOH
OCF ₃	H	CH ₃	CONH ₂
OCF ₃	H	H	CONHCH ₂ CONH ₂
OCF ₃	H	Cl	CH ₃
OCF ₃	H	Cl	CONH ₂


Case 21230YP

Page 17

R ⁶	R ⁷	R ²	R ¹
OCF ₃	H	H	NHCONH ₂
CF ₃	H	H	CH ₃
CF ₃	H	H	H
CF ₃	H	H	COOH
CF ₃	H	H	CONH ₂
CF ₃	H	H	
CF ₃	H	H	SH
CF ₃	H	H	S-COCH ₃
CF ₃	H	H	Cl
CF ₃	H	H	CN
CF ₃	H	H	
CF ₃	5-F	H	CH ₃
CF ₃	5-F	H	COOH
CF ₃	5-F	H	CONH ₂
CF ₃	4-F	H	CONH ₂
CF ₃	4-Cl	H	CONH ₂
Cl	6-Cl	H	CONH ₂
CF ₃	6-CF ₃	H	COOH
CF ₃	6-CF ₃	H	CONH ₂
CF ₃	4-CF ₃	H	CH ₃
CF ₃	4-CF ₃	H	COOH






Case 21230YP

Page 18

R ⁶	R ⁷	R ²	R ¹
CF ₃	4-CF ₃	H	CONH ₂
CF ₃	4-CF ₃	H	
O-Ph	H	H	CH ₃
O-Ph	H	H	COOH
O-Ph	H	H	CONH ₂
H	O-Ph	H	CONH ₂
Cl	H	H	CH ₃
H	3-Cl	H	CH ₃
-SO ₂ NH-tBu	H	H	CH ₃
-SO ₂ NH ₂	H	H	CH ₃
-CONH-tBu	H	H	CH ₃
-CONH ₂	H	H	CH ₃
-CONH-tBu	H	H	COOH
-CONH-tBu	H	H	CONH ₂
Cl	3-Cl	H	COOH
Cl	3-Cl	H	CONH ₂
Cl	3-Cl	H	COOCH ₃
-SO ₂ NH-tBu	H	H	COOH
-SO ₂ NH ₂	H	H	COOH
-SO ₂ NH-tBu	H	H	CONH ₂
-SO ₂ NH ₂	H	H	CONH ₂
OtBu	H	H	CH ₃



Case 21230YP

Page 19

R6	R7	R2	R1
OtBu	H	H	COOH
OtBu	H	H	CONH ₂
	H	H	CH ₃
	H	H	COOH
	H	H	CONH ₂
OCH ₂ CF ₃	H	H	CH ₃
OCH ₂ CF ₃	H	H	COOH
OCH ₂ CF ₃	H	H	CONH ₂
CHO	H	H	CONH ₂
H	3-CF ₃	H	CONH ₂
H	4-CF ₃	H	CONH ₂
H	3-F	H	CONH ₂
H	4-Cl	H	CONH ₂
H	4-F	H	CONH ₂
	H	H	CONH ₂
OCH ₃	3-OCH ₃	H	CONH ₂
OCH ₃	5-Cl	H	CONH ₂
CH ₃	H	H	CONH ₂
CH ₃	3-F	H	CONH ₂
	H	H	CONH ₂
H	4-(CH ₂ OH)	H	CONH ₂




Case 21230YP

Page 20

R6	R7	R2	R1
H	3-Cl	H	CONH ₂
H	3-OEt	H	CONH ₂
H	4-OEt	H	CONH ₂
F	H	H	CONH ₂
CH ₃	6-CH ₃	H	CONH ₂
H	4-tBu	H	CONH ₂
H	4-OCF ₃	H	CONH ₂
H	4-COCH ₃	H	CONH ₂
H	3-COCH ₃	H	CONH ₂
H	3-(CH ₂ OH)	H	CONH ₂
H	4-CN	H	CONH ₂
H	3-OCF ₃	H	CONH ₂
F	4-F	H	CONH ₂
H	H	H	CONH ₂
OCF ₃	4-N(Me)SO ₂ Me	H	CH ₃
OCF ₃	4-N(Me)SO ₂ Me	H	CONH ₂
OCF ₃	4-NHCO-tBu	H	CH ₃
OCF ₃	4-NHCO-tBu	H	COOH
OCF ₃	4-NHCO-tBu	H	CONH ₂
OCF ₃	H	H	
OCF ₃	H	H	


Case 21230YP

Page 21

R6	R7	R2	R1
OCF ₃	H	H	
OCF ₃	H	H	
OCF ₃	H	H	-CH ₂ CONH ₂
OCF ₃	H	H	-CH ₂ CN
OCF ₃	H	H	-SO ₂ NHtBu
OCF ₃	H	H	-SO ₂ NH ₂
OCF ₃	H	H	-SO ₂ NHMe
OCF ₃	H	H	-CH ₂ OH
OCF ₃	H	H	-CH(Me)OH
OCF ₃	H	H	-CH ₂ NHCOCH ₃
OCF ₃	H	H	-CH ₂ OSO ₂ NH ₂
OCF ₃	H	H	-NHCH ₃
OCF ₃	H	H	-NH-CH(CH ₃) ₂
OCF ₃	H	H	

or a pharmaceutically acceptable salt thereof.










35. (Original) The compound of Claim 1 represented by



A	R1
---	----


Case 21230YP

Page 22

	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂
	CONH ₂

or a pharmaceutically acceptable salt thereof.

36. (Original) The compound of Claim 1 represented by



R ₆	R ₄	R ₂	R ₁
OCF ₃	4-F	H	CH ₃
OCF ₃	4-F	H	COOH

Case 21230YP

Page 23

R ⁶	R ⁴	R ²	R ¹
OCF ₃	4-F	H	COOCH ₃
OCF ₃	4-F	H	CONH ₂
CF ₃	4-F	H	COOCH ₃
CF ₃	4-F	H	CONH ₂
CF ₃	4-F	H	CH ₃
OCF ₃	2-OCH ₂ Ph	H	CH ₃
OCF ₃	2-OH	H	CH ₃
OCF ₃	4-NHAc	H	CH ₃
OCF ₃	4-NHAc	H	COOCH ₃
OCF ₃	4-NHAc	H	CONH ₂
OCF ₃	2-F	H	CH ₃
OCF ₃	2-F	H	COOCH ₃
OCF ₃	2-F	H	CONH ₂
OCF ₃	4-Br	H	CH ₃
OCF ₃	4-Br	H	COOCH ₃
OCF ₃	4-Br	H	CONH ₂
OCF ₃	4-Br	H	COOH
OCF ₃	4-Ph	H	CH ₃
OCF ₃	4-Ph	H	COOCH ₃
OCF ₃	4-Ph	H	CONH ₂
OCF ₃	4-Cl	H	CH ₃
OCF ₃	4-Cl	H	COOCH ₃
OCF ₃	4-Cl	H	COOH
OCF ₃	4-Cl	H	CONH ₂
OCF ₃	2-Cl	H	CH ₃
OCF ₃	2-Cl	H	COOCH ₃
OCF ₃	2-Cl	H	CONH ₂
OCH ₂ CF ₃	4-F	H	CH ₃
OCH ₂ CF ₃	4-F	H	COOCH ₃
OCH ₂ CF ₃	4-F	H	COOH
OCH ₂ CF ₃	4-F	H	CONH ₂
H	4-OCH ₂ CF ₃	H	CONH ₂


Case 21230YP

Page 24

R ⁶	R ⁴	R ²	R ¹
OCF ₃	4-F	CH ₃	CH ₃
OCF ₃	4-F	CH ₃	COOCH ₃
OCF ₃	4-F	CH ₃	CONH ₂
F	4- OCH ₂ CF ₃	H	CONH ₂

or a pharmaceutically acceptable salt thereof.

37. (Currently Amended) The compound of Claim 1 represented by




R ⁶	R ¹
CF ₃	CH ₃
CF ₃	COOH
CF ₃	CONH ₂
OCF ₃	CH ₃
OCF ₃	COOH
OCF ₃	CONH ₂

or a pharmaceutically acceptable salt thereof.

38. (Original) A compound represented by


Case 21230YP

Page 25



or a pharmaceutically acceptable salt thereof.


39. (Original) The compound of Claim 1 represented by



R ⁶	R ¹
OCF ₃	CH ₃
OCF ₃	COOH
OCF ₃	COOCH ₃
OCF ₃	CONH ₂

or a pharmaceutically acceptable salt thereof.

40. (Original) The compound of Claim 1 represented by



R ⁶	R ¹
OCF ₃	CH ₃
OCF ₃	COOH
OCF ₃	CONH ₂
CF ₃	CH ₃
CF ₃	COOH
CF ₃	CONH ₂

Case 21230YP


Page 26

or a pharmaceutically acceptable salt thereof.

41. (Canceled)

42. (Canceled)

43. (Original) A compound represented by



or a pharmaceutically acceptable salt thereof.

44. (Original) A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

45. (Once Amended) The pharmaceutical composition according to Claim 44, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

46. (Canceled)

47. (Canceled)

48. (Canceled)

Case 21230YP

Page 27

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Canceled)

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Canceled)